Gossamer Bio Q2 2024 GAAP EPS $0.22 Beats $0.16 Estimate, Sales $95.842M Miss $114.286M Estimate
Portfolio Pulse from Benzinga Newsdesk
Gossamer Bio (NASDAQ:GOSS) reported Q2 2024 GAAP EPS of $0.22, beating the analyst estimate of $0.16 by 37.5%. However, the company's sales of $95.842 million missed the estimate of $114.286 million by 16.14%.

August 12, 2024 | 8:04 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Gossamer Bio reported Q2 2024 GAAP EPS of $0.22, beating the analyst estimate of $0.16 by 37.5%. However, the company's sales of $95.842 million missed the estimate of $114.286 million by 16.14%.
The earnings beat is a positive sign, indicating better-than-expected profitability. However, the significant miss on sales could raise concerns about the company's revenue growth and market performance. The mixed results are likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100